证券日报网讯2月9日，东方生物发布公告称，不存在逾期担保情况。 ...

每经AI快讯，东方生物2月9日晚间发布公告称，公司第三届第十七次董事会会议于2026年2月9日在公 司会议室以现场会议加通讯表决的方式召开。会议审议了《关于制定 <董事 高管薪酬制度="高管薪酬 制度"> 的议案》等文件。 （记者 曾健辉） 每经头条（nbdtoutiao）——美国名校毕业刚回国，26岁"金少"空降成董事长和总经理，父母隐退！A股 多位"00后"执掌要职，"不负投资者"成重大考验 ...

浙江东方基因生物制品股份有限公司 董事、高级管理人员薪酬制度 第一章 总 则 第一条 为进一步建立健全浙江东方基因生物制品股份有限公司（以下简称 "公司"）的内部激励和约束机制，充分发挥和调动董事、高级管理人员的工作 积极性和创造性，促进公司健康、稳定、可持续发展，根据《中华人民共和国公 司法》《上市公司治理准则》等法律、法规、规范性文件及《公司章程》等相关 规定，结合公司实际情况，制定本制度。 第二条 本制度适用于以下人员： （一）公司董事（含独立董事）； 浙江东方基因生物制品股份有限公司 董事、高级管理人员薪酬制度 （二）高级管理人员：包括公司总经理、副总经理、董事会秘书、财务负责 人及《公司章程》认定的其他高级管理人员。 第三条 本薪酬制度遵循以下基本原则： （一）公司董事和高级管理人员薪酬水平，应当与市场发展、行业周期与行 业水平相适应，与公司的经营业绩，与个人的岗位职责、岗位价值与业绩贡献相 匹配，与公司的可持续发展相协调。 （二）公司对董事和高级管理人员的绩效评价体系及激励约束机制应合理有 效，遵循公正、透明的原则，应当有利于增强公司创新发展能力，促进上市公司 可持续发展，服务于公司战略目标和持续 ...

证券代码：688298 证券简称：东方生物 公告编号：2026-004 估值提升计划 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 估值提升计划的触发情形及审议程序：自 2024 年 10 月 9 日至 2025 年 10 月 8 日，浙江东方基因生物制品股份有限公司（以下简称"公司"）股票连 续 12 个月每个交易日收盘价均低于最近一个会计年度经审计的每股归属于公司 普通股股东的净资产。根据《上市公司监管指引第 10 号——市值管理》，属于 应当制定估值提升计划的情形。本次估值提升计划经公司第三届董事会第十七次 会议审议通过； 估值提升计划概述：公司拟通过推进主营业务发展，持续压实"关键少 数"责任确保公司合规运行，优化信息披露质量，加强投资者关系管理，适时开 展或执行股份回购实施计划，探索现金分红方案等措施提升公司投资价值，增强 投资者信心，维护全体股东利益，促进公司高质量发展； 相关风险提示：本估值提升计划仅为公司行动计划，不代表公司对业绩、 股价、重大事件等任何指标或事项的承诺。公司业绩及二级市场表现 ...

证券代码：688298 证券简称：东方生物 公告编号：2026-005 浙江东方基因生物制品股份有限公司 关于子公司项目融资贷款暨公司为其提供担保的公告 累计担保情况 | 对外担保逾期的累计金额（万元） 0 | | | --- | --- | | | 公司及控股子公司对外担保总额 100,000.00（含本 | | 截至本公告日上市公司及其控股子公 | 次）； | | 司对外担保总额（万元） | 另外，公司以不动产向中国进出口银行浙江省分行 | | | 申请银行抵押贷款 1.15 亿元。 | | 对外担保总额占上市公司最近一期经 | 15.05 | | 审计净资产的比例（%） | | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一期经审 | | | 计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近一期 | | | 经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到或超 | | | 过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） 无 | | 一、担保情况概述 （一） ...

证券代码：688298 证券简称：东方生物 公告编号：2026-007 浙江东方基因生物制品股份有限公司 关于召开2026年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第二次临时股东会 召开日期时间：2026 年 2 月 26 日 10 点 00 分 召开地点：浙江省湖州市安吉县递铺街道阳光大道东段东方基因会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 26 日 至2026 年 2 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2026年2月26日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用 ...

证券代码：688298 证券简称：东方生物 公告编号：2026-006 浙江东方基因生物制品股份有限公司 第三届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）第三届董事会第 十七次会议于 2026 年 2 月 4 日以电子邮件及通讯形式发出会议通知，于 2026 年 2 月 9 日上午 10:00 在公司会议室以现场会议加通讯表决的方式召开。会议应 出席董事 7 名，实到出席董事 7 名。会议召开符合法律法规、《公司法》及《公 司章程》的相关规定。 会议由董事长方剑秋先生主持召开，全体与会董事经认真审议和表决，形成 以下决议： 1、审议通过了《关于公司估值提升计划的议案》 表决情况：本议案有效表决票 7 票，同意 7 票、反对 0 票、弃权 0 票。 根据《上市公司监管指引第 10 号——市值管理》，公司股票连续 12 个月每 个交易日收盘价均低于其近一个会计年度经审计的每股归属于公司普通股股东 的净资产，特制定本估值提升计划。 具体内容详见 ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

证券日报网讯1月30日，东方生物在互动平台回答投资者提问时表示，公司产品境外销售占比较高，主 要覆盖美国、欧洲等区域，公司销售采取经销为主、直销为辅的销售模式，以"东方基因""美国衡健"自 主品牌销售为主、辅以ODM方式销售。 ...

Group 1: Company Announcements - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder post-restructuring [1] - Silver Industry's gold and silver product revenues are low, with gold sales contributing 18.67% and silver 4.54% to total revenue in H1 2025 [2] - Tianneng Wind Power has decided to implement long-term production halts for six wholly-owned subsidiaries to optimize resource allocation and focus on core offshore wind power business [3] Group 2: Price and Supply Risks - Tongling Nonferrous Metals reports significant uncertainty in the prices of cathode copper and other main products, with low self-sufficiency in copper concentrate posing supply stability risks [4] - ST Aowei received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [5][6] Group 3: Performance Forecasts - Foton Motor expects a net profit increase of approximately 1551% to around 1.33 billion yuan in 2025, driven by sales growth across various segments [7] - Beimo High-Tech anticipates a net profit of 190 million to 220 million yuan, reflecting a growth of 1076.16% to 1261.87% [8] - Zhongke Sanhuan forecasts a net profit increase of 566.23% to 899.35%, driven by cost control and market expansion [9] - Wancheng Group expects a net profit of 1.23 billion to 1.4 billion yuan, a growth of 222.38% to 266.94% [10] - Wan Yi Technology anticipates a net profit increase of 191.52% to 330.34%, supported by product optimization and cost reduction measures [11] - Nanmo Biology expects a net profit of 24 million to 34 million yuan, a growth of 269.49% to 423.44% [12] - Bai'ao Saitou forecasts a net profit increase of 384.26% to 443.88%, benefiting from overseas market expansion [13] - Hailanxin anticipates a net profit of 40 million to 60 million yuan, a growth of 387.47% to 631.2% [14] - Panzhihua Coal expects a net profit of 318 million to 380 million yuan, a growth of 205.3% to 264.83% [15] - Huaguang New Materials forecasts a net profit increase of 104.67% to 141.88% [16] - Putian Technology expects a net profit of 1.92 million to 2.88 million yuan, a growth of 71.55% to 157.33% [17] - Guoda Special Materials anticipates a net profit increase of 82.61% [18] - Tongkun Co. expects a net profit of 1.95 billion to 2.15 billion yuan, a growth of 62.24% to 78.88% [19] - Yiming Pharmaceutical forecasts a net profit increase of 61.12% to 122.08% [20] - Guosheng Securities expects a net profit of 210 million to 280 million yuan, a growth of 25.44% to 67.25% [21] - Shengyi Technology anticipates a net profit increase of 87% to 98% [22] Group 4: Loss Forecasts - Saifutian expects a loss of 30 million to 45 million yuan, significantly reducing previous losses [23] - Magang Group forecasts a loss of 190 million to 250 million yuan, a substantial reduction in losses [24] - Shennong Seed Industry anticipates a profit of 90 million to 120 million yuan, reversing previous losses [25] - Jifeng Co. expects a profit of 410 million to 495 million yuan, reversing previous losses [26] - Bingchuan Network forecasts a profit of 436 million to 516 million yuan, reversing previous losses [27] - Zhongyou Technology anticipates a profit of 540 million to 640 million yuan, reversing previous losses [28] - Dongfang Biology expects a loss of 523 million yuan [29] - Wantai Biological anticipates a loss of 330 million to 410 million yuan due to market pressures [30] - Anbotong expects a loss of 114 million to 165 million yuan [31] - Shunxin Agriculture forecasts a loss of 116 million to 188 million yuan due to declining sales [32] - Guozhong Water expects a loss of 130 million to 104 million yuan, with potential delisting risks [33] Group 5: Major Contracts - China Communication Signal expects to win 21 major projects worth approximately 5.26 billion yuan [34]